Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation

Dyslipidemia is one of the complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is often underestimated and undertreated. Dyslipidemia in allo-HSCT recipients has been confirmed to be associated with endocrine dysfunction, acute and chronic graft-versus-host dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yingxue, Ma, Xiaojing, Pan, Jie, Ma, Rongqiang, Jiang, Yujie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344644/
https://www.ncbi.nlm.nih.gov/pubmed/35918766
http://dx.doi.org/10.1186/s12944-022-01665-3
_version_ 1784761264073867264
author Lu, Yingxue
Ma, Xiaojing
Pan, Jie
Ma, Rongqiang
Jiang, Yujie
author_facet Lu, Yingxue
Ma, Xiaojing
Pan, Jie
Ma, Rongqiang
Jiang, Yujie
author_sort Lu, Yingxue
collection PubMed
description Dyslipidemia is one of the complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is often underestimated and undertreated. Dyslipidemia in allo-HSCT recipients has been confirmed to be associated with endocrine dysfunction, acute and chronic graft-versus-host disease (aGVHD and cGVHD), immunosuppressive agent application, etc. However, few studies have illustrated the accurate molecular signaling pathways involved in dyslipidemia, and there are no standard guidelines for dyslipidemia management after HSCT. This review will discuss the pathogenesis of dyslipidemia, especially the association with aGVHD and/or cGVHD. Comprehensive treatment methods for dyslipidemia after HSCT will also be summarized. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12944-022-01665-3.
format Online
Article
Text
id pubmed-9344644
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93446442022-08-03 Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation Lu, Yingxue Ma, Xiaojing Pan, Jie Ma, Rongqiang Jiang, Yujie Lipids Health Dis Review Dyslipidemia is one of the complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is often underestimated and undertreated. Dyslipidemia in allo-HSCT recipients has been confirmed to be associated with endocrine dysfunction, acute and chronic graft-versus-host disease (aGVHD and cGVHD), immunosuppressive agent application, etc. However, few studies have illustrated the accurate molecular signaling pathways involved in dyslipidemia, and there are no standard guidelines for dyslipidemia management after HSCT. This review will discuss the pathogenesis of dyslipidemia, especially the association with aGVHD and/or cGVHD. Comprehensive treatment methods for dyslipidemia after HSCT will also be summarized. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12944-022-01665-3. BioMed Central 2022-08-02 /pmc/articles/PMC9344644/ /pubmed/35918766 http://dx.doi.org/10.1186/s12944-022-01665-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Lu, Yingxue
Ma, Xiaojing
Pan, Jie
Ma, Rongqiang
Jiang, Yujie
Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
title Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
title_full Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
title_fullStr Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
title_full_unstemmed Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
title_short Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
title_sort management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344644/
https://www.ncbi.nlm.nih.gov/pubmed/35918766
http://dx.doi.org/10.1186/s12944-022-01665-3
work_keys_str_mv AT luyingxue managementofdyslipidemiaafterallogeneichematopoieticstemcelltransplantation
AT maxiaojing managementofdyslipidemiaafterallogeneichematopoieticstemcelltransplantation
AT panjie managementofdyslipidemiaafterallogeneichematopoieticstemcelltransplantation
AT marongqiang managementofdyslipidemiaafterallogeneichematopoieticstemcelltransplantation
AT jiangyujie managementofdyslipidemiaafterallogeneichematopoieticstemcelltransplantation

Ejemplares similares